Entresto (sacubitril/valsartan) For Reducing Death, Hospitalization From Heart Failure | Sasha Gould, PharmD | RxEconsult
Menus

All Health Articles

Entresto (sacubitril/valsartan) For Heart Failure Reduces Cardiovascular Death And Hospitalization Category: Heart Disease by - July 9, 2015 | Views: 38179 | Likes: 3 | Comment: 0  

Entresto should not be used in the following situations.

  • Hypersensitivity to any component of Entresto
  • A history of angioedema related to ACEi or ARB treatment
  • Severe liver impairment 
  • Pregnant or breastfeeding
  • Combining Entresto with ACEi or aliskiren

Common side effects of Entresto include low blood pressure (hypotension), increased blood potassium (hyperkalemia), cough, and kidney impairment. Entresto may cause angioedema, a serious condition that causes swelling of the face, lips, throat, and tongue.  

The PARADIGM-HF trial demonstrated that Entresto is superior to enalapril, a gold standard medication for heart failure treatment. Improving survival is a significant benefit that will change the management of heart failure. Entresto has promise and can offer hope for millions of patients with heart failure. Future studies and clinical practice will clarify Entresto's place in therapy. People with heart failure should celebrate that a better treatment is now available.  

Also Read

Entresto (sacubitril/valsartan) Cost, Side Effects, Dosing, And Mechanism For Treating Heart Failure

LCZ696 and Other Congestive Heart Failure Medications in Development

FDA Approves Corlanor (ivabradine) For Reducing Hospitalization from Heart Failure

Corlanor (ivabradine) Side Effects, Dosage, Cost, Approval and Prescribing Information for Chronic Heart Failure

Guide for Congestive Heart Failure Treatment

LCZ696 and Other Congestive Heart Failure Medications in Development
- See more at: http://www.rxeconsult.com/healthcare-articles/LCZ696-and-Other-Congestive-Heart-Failure-Medications-in-Development-678/#sthash.edQAYrzB.dpuf
LCZ696 and Other Congestive Heart Failure Medications in Development
- See more at http://www.rxeconsult.com/healthcare-articles/LCZ696-and-Other-Congestive-Heart-Failure-Medications-in-Development-678/#sthash.edQAYrzB.dpuf

References

Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine.

Entresto Prescribing Information. FDA.gov

FDA Approves Entresto. FDA.gov

Heart Failure Fact Sheet. CDC.gov

 



For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2021 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap